DOP050. The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohn’s disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studies

Necrosis Factor Alpha ◽

Factor Alpha ◽

Post Hoc ◽

Alpha Antagonist ◽

Short-term histopathological response to anti-tumour necrosis factor alpha therapy in patients with ulcerative colitis

10.26226/morressier.596dfd59d462b80292387586 ◽

2017 ◽

Author(s):

Diana-Alexandra Costache

Keyword(s):

Ulcerative Colitis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Short Term ◽

Histopathological Response ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Alpha Therapy ◽

Faculty Opinions recommendation of Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1162910.623534 ◽

2009 ◽

Author(s):

Ulf Müller-Ladner

Keyword(s):

Tumour Necrosis Factor ◽

Dose Escalation ◽

Inflammatory Arthritis ◽

Tumour Necrosis ◽

Phase 1 ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Alpha Antagonist ◽

TUBERCULOSIS IN INFLAMMATORY BOWEL DISEASE UNDER TUMOUR NECROSIS FACTOR ALPHA ANTAGONIST – THE RISK BEYOND SCREENING

10.26226/morressier.59a6b34bd462b80290b559b1 ◽

2017 ◽

Author(s):

Carvalho Liliana

Keyword(s):

Inflammatory Bowel Disease ◽

Tumour Necrosis Factor ◽

Bowel Disease ◽

Tumour Necrosis ◽

Necrosis Factor Alpha ◽

Inflammatory Bowel ◽

Factor Alpha ◽

Alpha Antagonist ◽

Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab

Digestive and Liver Disease ◽

10.1016/j.dld.2007.06.003 ◽

2007 ◽

Vol 39 (9) ◽

pp. 811-817 ◽

Cited By ~ 25

Author(s):

C. Hassan ◽

E. Ierardi ◽

O. Burattini ◽

V. De Francesco ◽

A. Zullo ◽

...

Keyword(s):

Ulcerative Colitis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Down Regulation ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Treatment of Ocular Cicatricial Pemphigoid with the Tumour Necrosis Factor Alpha Antagonist Etanercept

Acta Dermato Venereologica ◽

10.2340/00015555-0132 ◽

2007 ◽

Vol 87 (1) ◽

pp. 74-75 ◽

Cited By ~ 23

Author(s):

S Prey ◽

PY Robert ◽

M Drouet ◽

A Sparsa ◽

C Roux ◽

...

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Cicatricial Pemphigoid ◽

Necrosis Factor Alpha ◽

Ocular Cicatricial Pemphigoid ◽

Factor Alpha ◽

Alpha Antagonist ◽

P982 Invasive cryptococcosis associated with treatment with adalimumab, a tumour necrosis factor alpha-antagonist agent

International Journal of Antimicrobial Agents ◽

10.1016/s0924-8579(07)70823-3 ◽

2007 ◽

Vol 29 ◽

pp. S260-S261

Author(s):

J.P. Horcajada ◽

J.L. Peña ◽

V.M. Martinez-Taboada ◽

T. Pina ◽

I. Belaustegui ◽

...

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Alpha Antagonist ◽

FRI0051 Decrease of disease activity and disability and improvement of quality of life in patients with refractory long-standing rheumatoid arthritis treated with monoclonal anti-tumour necrosis factor-alpha antibody

10.1136/annrheumdis-2001.1180 ◽

2001 ◽

Author(s):

F Fantini ◽

L Sinigaglia ◽

S Zeni ◽

M Cagnoli ◽

P Colombelli ◽

...

Keyword(s):

Quality Of Life ◽

Rheumatoid Arthritis ◽

Disease Activity ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Faculty Opinions recommendation of Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1162910.14148057 ◽

2011 ◽

Author(s):

Margriet Vervoordeldonk ◽

Caroline Aalbers

Keyword(s):

Tumour Necrosis Factor ◽

Dose Escalation ◽

Inflammatory Arthritis ◽

Tumour Necrosis ◽

Phase 1 ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Alpha Antagonist ◽

Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis

Alimentary Pharmacology & Therapeutics ◽

10.1111/apt.12644 ◽

2014 ◽

Vol 39 (7) ◽

pp. 660-671 ◽

Cited By ~ 100

Author(s):

R. W. Stidham ◽

T. C. H. Lee ◽

P. D. R. Higgins ◽

A. R. Deshpande ◽

D. A. Sussman ◽

...

Keyword(s):

Systematic Review ◽

Ulcerative Colitis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Meta Analysis ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Tumour necrosis factor-alpha (-308G/A) promoter polymorphism is associated with ulcerative colitis in Brazilian patients

International Journal of Immunogenetics ◽

10.1111/iji.12289 ◽

2016 ◽

Vol 43 (6) ◽

pp. 376-382 ◽

Cited By ~ 4

Author(s):

M. Tavares ◽

C. de Lima ◽

W. Fernandes ◽

V. Martinelli ◽

M. de Lucena ◽

...

Keyword(s):

Ulcerative Colitis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Promoter Polymorphism ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽